

## PROGRAM: 7<sup>TH</sup> EUROD WINTER MEETING JANUARY 2024

**\*\*\* Wednesday, Jan 17, 2024 \*\*\***

**13:30 – 13:35: Welcome (Pieter Evenepoel, UZ/KU Leuven, Belgium)**

**13:35 – 15:10: Young Investigator Workshop: Bone biopsy – from theory to practice**

*Get to know the transiliac bone biopsy technique from a practical angle, by rotating through three hands-on sessions of 25 minutes each, with ample time for interaction with the experts.*

**13:35 – 13:40: Introduction to the practical sessions (Maria Jesus Lloret, Hospital Fundació Puigvert, Barcelona, Spain)**

- Session A: **Bone Biopsy Hands-on** – a demonstration of equipment and technique  
(**Carina Ferreira**, Hospital Curry Cabral, Lisbon, Portugal)
- Session B: **Review of Basic Histomorphometry** – a look at the typical patterns of renal osteodystrophy (**Nathalie Bravenboer**, Amsterdam UMC, The Netherlands)
- Session C: **How to set it up** – what is needed to create a bone biopsy service?  
(**Marie-Helene Lafage-Proust**, St Etienne, France and **Ditte Hansen**, Copenhagen University Hospital-Herlev, Denmark)

**15:10 – 15:40: Coffee with an expert**

**15:40 – 18:00: Clinical Hot Topics**

*Gain a balanced view of calcium metabolism in CKD, including the upper and lower limit of recommended calcium intake across the spectrum of CKD, by reviewing a recent European consensus report on this issue. Learn about a novel bone imaging technique, Radiofrequency Echographic Multi Spectrometry, and what it can deliver compared to traditional dual-energy x-ray absorptiometry, when assessing fracture risk. Get an update on the challenges and opportunities of existing and emerging bone biomarkers for the evaluation of bone disease in CKD. Learn how to implement novel and sequential pharmacological approaches to target bone fragility in advanced CKD for your everyday clinical practice*

**15:40 – 15:50: Introduction to the session (Maria Fusaro, University of Padua, Italy)**

- 15:50–16:30 The recommended calcium intake in CKD – a European consensus  
(**Hanne Skou Jørgensen**, Aalborg University Hospital, Denmark)
- 16:30–16:50 DXA vs REMS: Differences and advantages (**Giuseppe Guglielmi**, Foggia University, Italy)
- 16:50–17:20 Bone biomarkers: a glimpse into the future (**Etienne Cavalier**, University of Liège, Belgium)
- 17:20–18:00 Novel and sequential pharmacological approaches in osteoporosis: how to apply in CKD (**Tom Nickolas**, Columbia University, New York, US)

**19:00: Meet & Greet in Leuven**

**\*\*\* Thursday, Jan 18, 2024 \*\*\***

**11:00 – 12:30: Satellite symposium – mineral metabolism and bone in rare renal diseases**

*Gain mechanistic insights into mineral and bone disorders by considering how rare renal disease may impact the CKD-MBD syndrome.*

- 11:00 – 11:10 Introduction (**Justine Bacchetta**, University of Lyon, France)
- 11:10 – 11:35 Throw me a bone: alkali in distal renal tubular acidosis  
(**Detlef Bockenhauer**, KU Leuven, Belgium)
- 11:35 – 12:00 Bone impairment in nephropathic cystinosis  
(**Justine Bacchetta**, University of Lyon, France)
- 12:00 – 12:30 X-Linked Hypophosphatemia  
(**Marie-Helene Lafage-Proust**, University of Lyon, St.Etienne, France)

**12:30 – 13:30: Lunch**

**13:30 – 18:00: Research Forum**

*The EUROD research forum gathers basic and clinical researchers, focusing on scientific progress in renal bone disease. The mission of the EUROD research forum is to share knowledge, foster collaboration, and enhance networking. The EUROD research forum comprises a mixture of invited mini lectures, selected free communications, and short pitches, with ample time for discussion.*

---

**13:30 – 15:00: Research Forum part 1**

- 13:30 – 13:50: Molecular diagnostics in CKD-MBD  
(**Sara Fernández-Villabril**, Central University Hospital of Asturias, Oviedo, Spain)
- 13:50 – 14:05 (FC): *To be decided*
- 14:05 – 14:20 (FC): *To be decided*
- 14:20 – 14:40: Male gonadal dysfunction and CKD-MBD (**Karel David**, KU Leuven, Belgium)
- 14:40 – 15:00: Hypoxia-driven pathways in bone development, regeneration and disease  
(**Christa Maes**, KU Leuven, Belgium)

**15:00 – 16:30: Coffee break and Guided poster tour**

**16:30 – 18:00: Research Forum part 2**

- 16:30 – 16:50: C-terminal FGF23 and its function in iron metabolism  
(**Guillaume Courbon**, University of Lyon, St.Etienne, France)
- 16:50 – 17:10: HIF stabilizers and CKD-MBD (**Marc Vervloet**, Amsterdam UMC, the Netherlands)
- 17:10 – 17:25 (FC): *To be decided*
- 17:25 – 17:40 (FC): *To be decided*
- 17:40 – 17:55: Spatial transcriptomics – advances and applications in bone research  
(**Thomas Levin Andersen**, Odense University, Denmark)

**18:00: Best Abstracts (Pieter Evenepoel, UZ/KU Leuven, Belgium)**

**19:00: Network Dinner (optional)**

**\*\*\* Friday, Jan 19, 2024 \*\*\***

**09:00 – 15:00: CME – Inflammation and CKD (–MBD)**

Systemic low grade inflammation is a common finding in patients with CKD. A plethora of endogenous and exogenous mediators are known to induce inflammation in CKD. Gut dysbiosis recently emerged as another important culprit. Inflammation may play a central role in the pathogenesis of chronic kidney disease and its cardiometabolic complications. Besides fueling

---

vascular calcification and bone loss, inflammation contributes to kidney disease progression and erythropoietin resistance. Insights from osteoimmunology and osteomicrobiology undoubtedly add another level of complexity to the pathogenesis of CKD-MBD. These novel insights create therapeutic opportunities, with drugs and nutraceuticals targeting inflammation either directly or indirectly rapidly gaining interest.

**09:00 – 09:10: Introduction (Pieter Evenepoel, UZ/KU Leuven, Belgium)**

**09:10 – 10:30: Pathogenesis of inflammation in CKD**

*Gain insights into the role of the innate immune system and inflammasome in the pathogenesis of sterile inflammation in CKD and how endogenous and exogenous factors mediate inflammation in the general population and in patients with CKD. Learn of the effects of a disturbed gut ecosystem on the pathogenesis of inflammation discover the “gut-bone axis” with potent links between hypogonadism, hyperparathyroidism, a disturbed gut ecosystem, and accelerated bone loss, by considering concepts from the emerging fields of osteoimmunology and osteomicrobiology.*

- 09:10 – 09:50 The essentials of sterile inflammation in CKD  
(**Thimoteus Speer**, Goethe University Hospital, Frankfurt, Germany)
- 09:50 – 10:30 Gut dysbiosis as a cause of inflammation in CKD  
(**Pieter Evenepoel**, UZ/KU Leuven, Belgium)

**10:30 – 11:10: Coffee break**

**11:10 – 12:30: Consequences of inflammation in CKD**

*Understand the importance of inflammation as a catalyst of vascular calcification and bone loss, with emphasis on the role of DNA damage response, senescence, and “inflammaging”. Gain insight in the involvement of inflammation in the pathogenesis of progression of CKD and the clinical relevance of the recently introduced SGLT-2 inhibitors and nonsteroidal MRAs in this context. Understand the contribution of inflammation to EPO hyporesponsiveness in CKD and how this may affect anemia management, particularly considering the novel HIF PH inhibitors.*

- 11:10 – 11:50 Inflammation and vascular calcification (**Cathy Shanahan**, King's College, London, UK)
- 11:50 – 12:30 Inflammation and bone loss: lessons from osteoimmunology and osteomicrobiology (**Roberto Pacifici**, Emory University, Atlanta, US)

**12:30 – 13:15: Lunch**

*Understand the contribution of inflammation to EPO hyporesponsiveness in CKD and how this may affect anemia management, particularly considering the novel HIF PH inhibitors.*

- 13:15 – 13:55 Inflammation and kidney disease progression (**Alberto Ortiz**, Jiménez Díaz Foundation University Hospital, Madrid, Spain)
- 13:55 – 14:35 EPO resistance in CKD: inflammation and beyond (**Lucia Del Vecchio**, Hospital Sant'Anna, Como, Italy)

**14:35 – 15:15: Targeting inflammation in CKD**

*Hear what is next on the horizon on how to target inflammation, focusing on nutraceuticals, senolytics, senomorphis and other therapies directly targeting inflammatory cytokines.*

- 14:35 – 15:15 Nutritional and pharmacological treatment options to tackle inflammation in CKD (**Peter Stenvinkel**, Karolinska Institute, Stockholm, Sweden)

**15:15: Concluding remarks** (Pieter Evenepoel, UZ/KU Leuven, Belgium)

**15:15 – 17:00: Coffee & Networking**

**19:00: Faculty dinner**

**\*\*\* Saturday, Jan 20, 2024 \*\*\***

**09:30 – 13:00: Belgian Bone Club Clinical Update Symposium**

**Long-term pharmacological treatment of osteoporosis: how and when to switch?**

(Area 42, Rue des Palais 46, **Brussels**; separate registration at <https://www.bcbonehealth.org/> )